Skip to main content
EJNMMI Radiopharmacy and Chemistry

Table 2 Comparison of the tumour and liver uptake of radioimmunoconjugates (RICs) estimated by region of interest (ROI) analysis of PET images and biodistribution (BOD) studies

From: Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy

Percent injected dose/g (mean ± SEM)

 

Tumour

Liver

Time p.i.

PET a

BOD b

P-value c

PET a

BOD b

P-value c

6 h

8.8 ± 2.3

9.3 ± 1.0

n.s.

11.2 ± 0.5

8.4 ± 0.8

n.s.

24 h

10.3 ± 1.3

14.9 ± 1.1

n.s.

9.5 ± 0.2

7.5 ± 1.0

n.s.

48 h

10.9 ± 1.1

9.8 ± 1.3

n.s.

7.2 ± 0.3

6.2 ± 0.1

0.04

  1. aUptake of [64Cu]Cu-DOTA-panitumumab Fab´)2 estimated by ROI analysis of PET images expressed in percent injected dose/g (%ID/g; mean ± SEM, n = 4)
  2. bUptake of [64Cu]Cu-DOTA-panitumumab F(ab´)2 estimated by BOD analysis expressed in %ID/g (mean ± SEM, n = 4)
  3. cComparison of ROI and BOD analysis by a Mann-Whitney U test (P < 0.05)
Back to article page